Leerink Partners analyst Richard Newitter maintained a Buy rating on Globus Medical (NYSE: GMED) today and set a price target of $61. The company’s shares closed yesterday at $54.62, close to its 52-week high of $54.68.
Newitter has an average return of 8.6% when recommending Globus Medical.
According to TipRanks.com, Newitter is ranked #95 out of 4811 analysts.
Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $57.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $54.68 and a one-year low of $27.79. Currently, Globus Medical has an average volume of 669.5K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. Most recently, in March 2018, David Davidar, a Director at GMED sold 70,000 shares for a total of $3,535,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments.
